{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:49:00Z","timestamp":1748868540802,"version":"3.40.5"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.tem.2024.04.002","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T20:24:25Z","timestamp":1713385465000},"page":"765-768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pediatric thyroid side effects of immune checkpoint inhibitors"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2560-6508","authenticated-orcid":false,"given":"Cesare","family":"Morgante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-9754","authenticated-orcid":false,"given":"Alessandra","family":"Fierabracci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3795-5693","authenticated-orcid":false,"given":"Armando","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2024.04.002_bb0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tem.2024.04.002_bb0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.10029","article-title":"Phase 1 clinical trial of durvalumab in children with solid and central nervous system tumors","volume":"40","author":"Mascarenhas","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tem.2024.04.002_bb0015","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1158\/1078-0432.CCR-22-2164","article-title":"A phase I\/II trial of nivolumab plus ipilimumab in children and young adults with relapsed\/refractory solid tumors: a Children\u2019s Oncology Group Study ADVL1412","volume":"28","author":"Davis","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tem.2024.04.002_bb0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1\u20132 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tem.2024.04.002_bb0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","article-title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1\u20132 study","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tem.2024.04.002_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.tem.2024.04.002_bb0035","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.3389\/fimmu.2018.02374","article-title":"Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression","volume":"9","author":"Gianchecchi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tem.2024.04.002_bb0040","first-page":"1","article-title":"Checkpoint immunotherapy in pediatrics: here, gone, and back again","volume":"41","author":"Long","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.tem.2024.04.002_bb0045","first-page":"1008","article-title":"Thyroid disorders in children and adolescents: a review JAMA","volume":"170","author":"Hanley","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.tem.2024.04.002_bb0050","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00262-022-03159-8","article-title":"Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1\/2 trial","volume":"71","author":"Loeb","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tem.2024.04.002_bb0055","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.3390\/cancers13215277","article-title":"The continuum of thyroid disorders related to immune checkpoint inhibitors: still many pending queries","volume":"13","author":"Deligiorgi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tem.2024.04.002_bb0060","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tem.2024.04.002_bb0065","first-page":"2075","article-title":"Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Harker-Murray","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tem.2024.04.002_bb0070","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2024.04.002_bb0075","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/EJE-17-0054","article-title":"Endocrine late-effects of childhood cancer and its treatments","volume":"176","author":"Chemaitilly","year":"2017","journal-title":"Eur. J. Endocrinol."}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276024000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276024000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T14:46:10Z","timestamp":1725893170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276024000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1043276024000857"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2024.04.002","relation":{},"ISSN":["1043-2760"],"issn-type":[{"type":"print","value":"1043-2760"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric thyroid side effects of immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2024.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}